PA8699501A1 - Tetrahidroquinolinas, su sintesis e intermediarios - Google Patents

Tetrahidroquinolinas, su sintesis e intermediarios

Info

Publication number
PA8699501A1
PA8699501A1 PA20068699501A PA8699501A PA8699501A1 PA 8699501 A1 PA8699501 A1 PA 8699501A1 PA 20068699501 A PA20068699501 A PA 20068699501A PA 8699501 A PA8699501 A PA 8699501A PA 8699501 A1 PA8699501 A1 PA 8699501A1
Authority
PA
Panama
Prior art keywords
disorders
psycho
psychosis
compounds
school
Prior art date
Application number
PA20068699501A
Other languages
English (en)
Inventor
B Feigelson Gregg
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8699501A1 publication Critical patent/PA8699501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION PROPORCIONA METODOS PARA PREPARAR COMPUESTOS QUE TIENEN ACTIVIDAD COMO AGONISTAS O AGONISTAS PARCIALES DE 5HT 2C. DICHOS COMPUESTOS SON UTILES PARA TRATAR LA ESQUIZOFRENIFORME, EL TRASTORNO ESQUIZOAFECTIVO, EL TRASTORNO DELUSIONAL, EL TRASTORNO PSICOTICO INDUCIDO POR SUSTANCIAS, LA PSICOSIS INDUCIDA POR L-DOPA, LA PSICOSIS ASOCIADA CON LA DEMENCIA DE ALZHEIMER, LA PSICOSIS ASOCIADA CON EL MAL DE PARKINSON, LA PSICOSIS ASOCIADA CON LA ENFERMEDAD DE LOS CUERPOS DE LEWY, DEMENCIA, DEFICIT DE MEMORIA, DEFICIT INTELECTUAL ASOCIADO CON EL MAL DE ALZHEIMER, TRASTORNOS BIPOLARES, TRASTORNOS DEPRESIVOS, TRASTORNOS DEL HUMOR, TRASTORNOS DE ANSIEDAD, TRASTORNOS DE ADAPTACION, TRASTORNOS ALIMENTICIOS, EPILEPSIA, TRASTORNOS DEL SUEÑO, MIGRAÑA, DISFUNCION SEXUAL, TRASTORNOS GASTROINTESTINALES, OBESIDAD Y DEFICIENCIA DEL SISTEMA NERVIOSO CENTRAL ASOCIADA CON TRAUMATISMOS, APOPLEJIA O LESION DE LA MEDULA ESPINAL. TALES COMPUESTOS INCLUYEN A LOS DE FORMULA I.
PA20068699501A 2005-10-17 2006-10-17 Tetrahidroquinolinas, su sintesis e intermediarios PA8699501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72760605P 2005-10-17 2005-10-17

Publications (1)

Publication Number Publication Date
PA8699501A1 true PA8699501A1 (es) 2009-06-23

Family

ID=37681506

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20068699501A PA8699501A1 (es) 2005-10-17 2006-10-17 Tetrahidroquinolinas, su sintesis e intermediarios

Country Status (18)

Country Link
US (1) US20070088022A1 (es)
EP (1) EP1937684A2 (es)
JP (1) JP2009511633A (es)
KR (1) KR20080057286A (es)
CN (1) CN101331130A (es)
AR (1) AR056695A1 (es)
AU (1) AU2006304480A1 (es)
BR (1) BRPI0617483A2 (es)
CA (1) CA2626215A1 (es)
CR (1) CR9872A (es)
EC (1) ECSP088383A (es)
IL (1) IL190549A0 (es)
NO (1) NO20081621L (es)
PA (1) PA8699501A1 (es)
PE (1) PE20070549A1 (es)
RU (1) RU2008113221A (es)
TW (1) TW200800986A (es)
WO (1) WO2007047671A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
US20070225278A1 (en) * 2006-03-24 2007-09-27 Wyeth Methods for treating cognitive and other disorders
CN101410118A (zh) * 2006-03-24 2009-04-15 惠氏公司 疼痛的治疗
WO2007112073A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US9359303B2 (en) 2009-04-21 2016-06-07 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
ES2338119T3 (es) * 2003-04-21 2010-05-04 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor-beta de estrogeno.

Also Published As

Publication number Publication date
US20070088022A1 (en) 2007-04-19
ECSP088383A (es) 2008-05-30
CN101331130A (zh) 2008-12-24
IL190549A0 (en) 2008-11-03
NO20081621L (no) 2008-05-06
BRPI0617483A2 (pt) 2011-07-26
EP1937684A2 (en) 2008-07-02
PE20070549A1 (es) 2007-06-15
CA2626215A1 (en) 2007-04-26
WO2007047671A3 (en) 2007-10-04
WO2007047671A2 (en) 2007-04-26
AU2006304480A1 (en) 2007-04-26
AR056695A1 (es) 2007-10-17
RU2008113221A (ru) 2009-11-27
JP2009511633A (ja) 2009-03-19
CR9872A (es) 2008-08-21
KR20080057286A (ko) 2008-06-24
TW200800986A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
PA8699501A1 (es) Tetrahidroquinolinas, su sintesis e intermediarios
GT200500297A (es) Sintesis asimetrica de dehidrobenzofuranos sustituidos
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
PA8815001A1 (es) Piridinil amidas para el tratamiento de trastornos del snc y metabolicos
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CU20100049A7 (es) Derivados de bencimidazol e indol sustituidos por oxadiazol y oxasol como inhibidores de dgat1
GT200500336A (es) Derivados de 3-fenil-pirazol como moduladores del receptor 5ht 2a de la serotonina utiles para el tratamiento de trastornos relacionados con este
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
CL2008002744A1 (es) Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2.
CR8992A (es) Analogos de biaril piperazinilpiridina sustituida
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
GT200000019A (es) Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc.
GT200800033A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CL2011000137A1 (es) Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
SV2009002917A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos